Showing results (71-80 of 646) with videos related to

Sort By:
Pageof 65
Leukemia & Lymphoma|November 6, 2012
Geography, ethnicity and "roots" in chronic lymphocytic leukemiaRosa Ruchlemer, Aaron Polliack
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|March 29, 2018
Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell DyscrasiasTamar Tadmor, Ilana Levy, Zahava Vadasz
Expert Review of Hematology|November 22, 2017
A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemiaTamar Tadmor, Manfred Welslau, Iwona Hus
Blood|February 27, 2023
Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surgeTamar Tadmor, Hilel Alapi, Lior Rokach
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 2, 2005
Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic optionsYair Herishanu, Aaron Polliack
Seminars in Hematology|February 24, 2026
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical managementOla Landgren, Rafat Abonour, Dickran Kazandjian
Leukemia & Lymphoma|September 5, 2022
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscapeDickran Kazandjian, Andrew Kowalski, Ola Landgren
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The road to treating smoldering multiple myelomaNeha Korde, Sham Mailankody, Ola Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disordersGary A Ulaner, C Ola Landgren
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
Pageof 65